MASI.NASDAQMasimo CORP

Form 4: Masimo Corp Director Robert A. Chapek Acquires 1,790 Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Robert A. Chapek, a director of Masimo Corp, acquired 1,790 restricted stock units (RSUs) on September 19, 2024, which will vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Summary

  • On September 19, 2024, Robert A. Chapek, a director of Masimo Corp, acquired 1,790 restricted stock units (RSUs).
  • Each RSU represents the right to receive one share of Masimo Corp common stock upon vesting.
  • The RSUs will vest in full on the earlier of September 19, 2025, or the date of the next annual meeting of stockholders following the grant date.
  • Following the transaction, Chapek directly owns 1,790 derivative securities.
  • The expiration date of the derivative securities is September 19, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating an insider transaction. The grant of RSUs is generally viewed as a positive sign, aligning director interests with shareholders, but it's not a major event.

Positives

  • The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects, but the RSU grant suggests a long-term alignment of the director's interests with those of the shareholders.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings of company directors. It's a common practice for companies to grant stock-based compensation to align management and director incentives with shareholder value.

Comparison to Industry Standards

  • Stock-based compensation is a common practice across the industry to incentivize executives and align their interests with shareholders.
  • Companies like Medtronic, Boston Scientific, and Abbott also utilize similar compensation structures.
  • The vesting schedule and terms of the RSUs are generally in line with industry standards for executive compensation.

Stakeholder Impact

  • The RSU grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

DateDescription
09/19/2024Date of transaction: Robert A. Chapek acquired 1,790 restricted stock units.
09/19/2025RSUs will vest in full on the earlier of this date or the date of the next annual meeting of stockholders following the grant date.
09/19/2034Expiration date of the derivative securities.
09/23/2024Date of signature by Attorney-In-Fact.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.